Skip Therapeutics

Company Overview

Snapshot

Founded in January 2021 by Ariel Feiglin, Skip Therapeutics operates with 1–10 employees. The company has secured funding across one round from two investors, including RMGP Biopharma Investment Fund and FutuRx. In May 2021, the company received its Seed funding.

Business overview

Skip Therapeutics is a Health Tech & Life Sciences company focused on developing personalized RNA-based treatments for rare genetic diseases. The company utilizes a proprietary computational engine and bioinformatic pipeline to analyze disease-causing mutations and identify optimal molecular strategies for restoring protein function using splice-modulating antisense oligonucleotides (ASOs). This approach enables the identification of treatable patient cohorts and optimizes target selection, with top candidates undergoing experimental validation for therapeutic development. Skip Therapeutics operates within the Pharmaceuticals, Biotechnology, and Drug Discovery & Development sectors, serving the Life Sciences and Biotechnology markets.

Company Intelligence Q&A

What is Skip Therapeutics' primary focus?

Skip Therapeutics develops personalized RNA-based treatments for rare genetic diseases in directly identified patients and patient cohorts.

When was Skip Therapeutics founded?

Skip Therapeutics was founded in January 2021.

Who is a co-founder of Skip Therapeutics?

Ariel Feiglin is a co-founder and CSO of Skip Therapeutics.

What technology does Skip Therapeutics use?

Skip Therapeutics uses a novel, proprietary computational engine and bioinformatic pipeline to analyze disease-causing mutations and identify molecular strategies for restoring protein function.

Which investors participated in Skip Therapeutics' Seed funding round?

In May 2021, Skip Therapeutics received Seed funding from investors including.